

PRECEPTORSHIP PROGRAMME

Non-Small-Cell Lung Cancer (NSCLC)

Standards of care, evolving paradigm
and future perspectives

SINGAPORE

20-21 NOVEMBER 2019

Co-Chairs

David Planchard, FR
Ross A. Soo, SG

ESMO PRECEPTORSHIP PROGRAMME NON-SMALL-CELL LUNG CANCER

Standards of care, evolving paradigm and future perspectives

Singapore
20-21 November 2019

CO-CHAIRS:

David Planchard, France
Ross A. Soo, Singapore

SPEAKERS:

Myung-Ju Ahn, South Korea	Pyng Lee, Singapore
Fabrice Barlesi, France	Tetsuya Mitsudomi, Japan
Byoung Chul Cho, South Korea	Silvia Novello, Italy
Teh-Ying Chou, Taiwan	Ivan Tham, Singapore
Steven C.-H. Kao, Australia	

LEARNING OBJECTIVES

- To learn about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting
- To understand the importance of pathology and histoprognostic factors in the management of NSCLC
- To learn about the management of patients after progression, side effects of treatments and the use of targeted agents in NSCLC

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 20 November 2019

09:00-09:10 10'	Opening and welcome	David Planchard, FR Ross A. Soo, SG
10'	Welcome from ESMO, objectives and scientific introduction	David Planchard, FR
09:10-10:50 100'	SESSION 1 Screening, diagnosis and staging	Chair: Steven C.-H. Kao, AU
30'	Lung cancer screening: Current data and screening in the Asian setting	Pyng Lee, SG
30'	Lung cancer diagnosis: Role of pathology and genetic analysis	Teh-Ying Chou, TW
30'	Lung cancer: Additional investigation after diagnosis	Silvia Novello, IT
10'	Discussion	Faculty
10:50-11:20	Coffee break	
11:20-12:20 60'	SESSION 2 Adjuvant therapy	Chair: Silvia Novello, IT
30'	Adjuvant/Neo-adjuvant chemotherapy for resected NSCLC	Silvia Novello, IT
30'	Adjuvant and neo-adjuvant radiotherapy	Ivan Tham, SG
12:20-13:20	Lunch	
13:20-14:40 80'	SESSION 3 Multi-disciplinary lung tumour board	Chair: Ross A. Soo, SG
40'	Management of stage III - Case presentation <ul style="list-style-type: none"> - Radiotherapist's point of view - Medical oncologist's point of view - Surgeon's point of view - Discussion 	Ivan Tham, SG Fabrice Barlesi, FR Tetsuya Mitsudomi, JP
40'	Management of oligometastatic disease - Case presentation <ul style="list-style-type: none"> - Radiotherapist's point of view - Medical oncologist's point of view - Surgeon's point of view - Discussion 	Ivan Tham, SG Fabrice Barlesi, FR Tetsuya Mitsudomi, JP
14:40-15:10	Coffee break	
15:10-16:10 60'	SESSION 4 Audience cases	Chairs: David Planchard, FR Ross A. Soo, SG
60'	Participants clinical case discussion (3x20')	Faculty
16:10-17:35 85'	SESSION 5 Systemic therapy for advanced NSCLC	Chair: Tetsuya Mitsudomi, JP
45'	Immune checkpoint inhibitors (including first-line and beyond)	Myung-Ju Ahn, KR
20'	Management of IO toxicities	Fabrice Barlesi, FR
20'	Discussion	Faculty
19:30	Dinner	

Thursday, 21 November 2019

08:30-11:30 150'	SESSION 6 Targeted therapies	Chair: Myung-Ju Ahn, KR
30'	Systemic therapy for non-oncogene addicted NSCLC	Ross A. Soo, SG
30'	New treatment options for EGFR + NSCLC	Tetsuya Mitsudomi, JP
30'	New treatment options for ALK + NSCLC	David Planchard, FR
10:00-10:30	Coffee break	
20'	Targeted therapy beyond EGFR/ALK: BRAF, ROS1	David Planchard, FR
20'	Targeted therapy beyond EGFR/ALK: RET, MET, NTRK	Byoung Chul Cho, KR
20'	Discussion	Faculty
11:30-12:30 60'	SESSION 7 Audience cases	Chairs: David Planchard, FR Ross A. Soo, SG
60'	Participants clinical case discussion (3x20')	Faculty
12:30-13:30	Lunch	
13:30-14:50 80'	SESSION 8 Other thoracic tumours and molecular testing	Chair: Fabrice Barlesi, FR
20'	Small-Cell Lung Cancer	Steven C.-H. Kao, AU
20'	Malignant mesothelioma	Steven C.-H. Kao, AU
20'	Liquid biopsy	Fabrice Barlesi, FR
20'	Discussion	Faculty
14:50-15:00 10'	Conclusion and take home messages	David Planchard, FR Ross A. Soo, SG

Note: Each 20 minute slot for clinical case discussion includes 10' case presentation and 10' Q&A / panel discussion